Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPG7236 Phase 1 dose escalation in healthy volunteers
NCT05288543Phase 1Terminated
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd.
- Start
- Apr 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IPG7236 in atopic dermatitis (AD) (3 arms), sponsored by Nanjing Immunophage Biotech Co., Ltd. Primary endpoint: Adverse Events at 36 days. Started Apr 2022; status: terminated.
02
Drugs
IPG7236
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05288543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05288543.